Tongue cancer epidemiology and demographics: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
|||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tongue cancer}} | {{Tongue cancer}} | ||
{{CMG}}{{AE}}{{Simrat}} | {{CMG}}; {{AE}} {{Simrat}} {{MAD}} | ||
==Overview== | ==Overview== | ||
In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. There is no racial predilection to the tongue cancer. | In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. There is no racial predilection to the tongue cancer. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
In the United States, cancers of the oral cavity represent 2% of all cancers diagnosed annually. In Australia and Europe, the incidence of oral cavity cancer is very low, accounting for less than 5% of all cancers. In France, oral cavity cancer is the third most common cancer in males and the second most common cause of death from cancer. | In the United States, cancers of the [[oral cavity]] represent 2% of all cancers diagnosed annually. In Australia and Europe, the incidence of oral cavity cancer is very low, accounting for less than 5% of all cancers. In France, oral cavity cancer is the third most common cancer in males and the second most common cause of death from cancer.<ref name="pmid22752881">{{cite journal| author=Bray F, Ren JS, Masuyer E, Ferlay J| title=Global estimates of cancer prevalence for 27 sites in the adult population in 2008. | journal=Int J Cancer | year= 2013 | volume= 132 | issue= 5 | pages= 1133-45 | pmid=22752881 | doi=10.1002/ijc.27711 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22752881 }}</ref><ref name="SEER">Cancer of the oral cavity and pharynx. SEER(2015) http://seer.cancer.gov/csr/1975_2012/results_merged/sect_20_oral_cavity_pharynx.pdf#search=tongue+cancer Accessed on November 28, 2015</ref> | ||
===Incidence=== | ===Incidence=== | ||
In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Approximately one in 324 men and women will be diagnosed with tongue cancer in their lifetime. According to the National Cancer Institute in the year 2011, the incidence of tongue cancer was estimated to be approximately 12,060 cases per 100, 000 individuals. Out of those approximately 71% ( | In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Approximately one in 324 men and women will be diagnosed with tongue cancer in their lifetime. According to the [[National Cancer Institute]] in the year 2011, the incidence of tongue cancer was estimated to be approximately 12,060 cases per 100, 000 individuals. Out of those approximately 71% ( i.e, 8,560) were men and 29% ( i.e, 3,500) were women.<ref name="SEER">Cancer of the oral cavity and pharynx. SEER(2015) http://seer.cancer.gov/csr/1975_2012/results_merged/sect_20_oral_cavity_pharynx.pdf#search=tongue+cancer Accessed on November 28, 2015</ref> | ||
===Gender=== | ===Gender=== | ||
Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. | Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1.<ref name="pmid28055103">{{cite journal| author=Siegel RL, Miller KD, Jemal A| title=Cancer Statistics, 2017. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 1 | pages= 7-30 | pmid=28055103 | doi=10.3322/caac.21387 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28055103 }}</ref> | ||
===Race=== | ===Race=== | ||
There is no racial predilection to the tongue cancer. | There is no racial predilection to the tongue cancer.<ref name="pmid26421817">{{cite journal| author=Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L et al.| title=Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. | journal=Eur J Cancer | year= 2015 | volume= 51 | issue= 15 | pages= 2130-2143 | pmid=26421817 | doi=10.1016/j.ejca.2015.07.043 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26421817 }}</ref> | ||
===Age=== | ===Age=== | ||
The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. | The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. | ||
According to the National Cancer Institute from 2004-2008, the age at diagnosis and percentage of people diagnosed with tongue cancer are shown below:<ref name="SEER"> | According to the National Cancer Institute from 2004-2008, the age at diagnosis and percentage of people diagnosed with tongue cancer are shown below:<ref name="SEER">Cancer of the oral cavity and pharynx. SEER(2015) http://seer.cancer.gov/csr/1975_2012/results_merged/sect_20_oral_cavity_pharynx.pdf#search=tongue+cancer Accessed on November 28, 2015</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align="center" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Age at diagnosis}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Age at diagnosis}} | ||
| Line 62: | Line 68: | ||
|- | |- | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
Latest revision as of 15:42, 21 December 2017
|
Tongue cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tongue cancer epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Tongue cancer epidemiology and demographics |
|
Risk calculators and risk factors for Tongue cancer epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. There is no racial predilection to the tongue cancer.
Epidemiology and Demographics
In the United States, cancers of the oral cavity represent 2% of all cancers diagnosed annually. In Australia and Europe, the incidence of oral cavity cancer is very low, accounting for less than 5% of all cancers. In France, oral cavity cancer is the third most common cancer in males and the second most common cause of death from cancer.[1][2]
Incidence
In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Approximately one in 324 men and women will be diagnosed with tongue cancer in their lifetime. According to the National Cancer Institute in the year 2011, the incidence of tongue cancer was estimated to be approximately 12,060 cases per 100, 000 individuals. Out of those approximately 71% ( i.e, 8,560) were men and 29% ( i.e, 3,500) were women.[2]
Gender
Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1.[3]
Race
There is no racial predilection to the tongue cancer.[4]
Age
The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. According to the National Cancer Institute from 2004-2008, the age at diagnosis and percentage of people diagnosed with tongue cancer are shown below:[2]
| Age at diagnosis | percentage of people diagnosed with tongue cancer |
|---|---|
|
0.2% of all tongue cancer diagnosis |
|
2.0% of all tongue cancer diagnosis |
|
6.0% of all tongue cancer diagnosis |
|
20.8% of all tongue cancer diagnosis |
|
31% of all tongue cancer diagnosis |
|
21.9% of all tongue cancer diagnosis |
|
13.5% of all tongue cancer diagnosis |
|
4.6% of all tongue cancer diagnosis |
References
- ↑ Bray F, Ren JS, Masuyer E, Ferlay J (2013). "Global estimates of cancer prevalence for 27 sites in the adult population in 2008". Int J Cancer. 132 (5): 1133–45. doi:10.1002/ijc.27711. PMID 22752881.
- ↑ 2.0 2.1 2.2 Cancer of the oral cavity and pharynx. SEER(2015) http://seer.cancer.gov/csr/1975_2012/results_merged/sect_20_oral_cavity_pharynx.pdf#search=tongue+cancer Accessed on November 28, 2015
- ↑ Siegel RL, Miller KD, Jemal A (2017). "Cancer Statistics, 2017". CA Cancer J Clin. 67 (1): 7–30. doi:10.3322/caac.21387. PMID 28055103.
- ↑ Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L; et al. (2015). "Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study". Eur J Cancer. 51 (15): 2130–2143. doi:10.1016/j.ejca.2015.07.043. PMID 26421817.